News headlines about Edwards Lifesciences Corporation (NYSE:EW) have been trending somewhat positive on Monday, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Edwards Lifesciences Corporation earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 75 out of 100, meaning that recent press coverage is likely to have an impact on the stock’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Edwards Lifesciences Corporation (EW) Cut to “Hold” at Zacks Investment Research (americanbankingnews.com)
- Edwards Lifesciences Corporation (EW) Price Target Raised to $14.00 at SunTrust Banks, Inc. (americanbankingnews.com)
- Edwards Lifesciences Corporation (NYSE:EW) Set to Announce Quarterly Earnings on Monday (americanbankingnews.com)
- Edwards Lifesciences Corporation (EW) Given Consensus Recommendation of “Buy” by Analysts (americanbankingnews.com)
- Abbott Partners Bigfoot Biomedical to Expand in Diabetics – Nasdaq (nasdaq.com)
Edwards Lifesciences Corporation (EW) traded down 0.55% during trading on Monday, reaching $116.28. 489,594 shares of the company were exchanged. Edwards Lifesciences Corporation has a 52-week low of $81.12 and a 52-week high of $121.75. The stock has a market capitalization of $24.40 billion, a PE ratio of 38.66 and a beta of 0.63. The firm’s 50 day moving average is $115.58 and its 200 day moving average is $100.62.
Edwards Lifesciences Corporation (NYSE:EW) last issued its earnings results on Tuesday, April 25th. The medical research company reported $0.94 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.82 by $0.12. Edwards Lifesciences Corporation had a return on equity of 25.80% and a net margin of 20.85%. The firm had revenue of $883.50 million for the quarter, compared to analyst estimates of $776.51 million. During the same period last year, the company earned $0.71 earnings per share. The firm’s revenue for the quarter was up 26.7% on a year-over-year basis. Analysts expect that Edwards Lifesciences Corporation will post $3.53 EPS for the current year.
EW has been the subject of several recent research reports. Northland Securities set a $105.00 price objective on shares of Edwards Lifesciences Corporation and gave the company a “buy” rating in a research note on Monday, March 20th. Vetr lowered shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating and set a $105.74 price objective for the company. in a research note on Monday, March 27th. Evercore ISI raised shares of Edwards Lifesciences Corporation from an “in-line” rating to an “outperform” rating and raised their price objective for the company from $98.50 to $110.00 in a research note on Monday, March 27th. Cowen and Company reissued an “outperform” rating and issued a $120.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Tuesday, March 28th. Finally, Stifel Nicolaus raised their price objective on shares of Edwards Lifesciences Corporation from $114.00 to $118.00 and gave the company a “buy” rating in a research note on Wednesday, April 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. Edwards Lifesciences Corporation has a consensus rating of “Buy” and an average price target of $117.03.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Likely to Affect Edwards Lifesciences Corporation (EW) Share Price” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/2722845/somewhat-positive-press-coverage-likely-to-affect-edwards-lifesciences-corporation-ew-share-price.html.
In other Edwards Lifesciences Corporation news, CEO Michael A. Mussallem sold 49,100 shares of the stock in a transaction on Friday, April 28th. The stock was sold at an average price of $109.78, for a total value of $5,390,198.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP Bernard J. Zovighian sold 18,050 shares of the stock in a transaction on Thursday, April 27th. The stock was sold at an average price of $109.21, for a total value of $1,971,240.50. The disclosure for this sale can be found here. Insiders sold 252,101 shares of company stock worth $28,141,680 over the last ninety days. 2.13% of the stock is owned by corporate insiders.
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.